rifampin and Embolism

rifampin has been researched along with Embolism* in 4 studies

Other Studies

4 other study(ies) available for rifampin and Embolism

ArticleYear
Physiologically-Based Pharmacokinetic Modeling for the Prediction of a Drug-Drug Interaction of Combined Effects on P-glycoprotein and Cytochrome P450 3A.
    CPT: pharmacometrics & systems pharmacology, 2020, Volume: 9, Issue:11

    Direct oral anticoagulants, such as apixaban and rivaroxaban, are important for the treatment and prophylaxis of venous thromboembolism and to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Because apixaban and rivaroxaban are predominantly eliminated by cytochrome P450 (CYP) 3A and P-glycoprotein (P-gp), concomitant use of combined P-gp and strong CYP3A4 inhibitors and inducers should be avoided. Physiologically-based pharmacokinetic models for apixaban and rivaroxaban were developed to estimate the net effect of CYP3A induction, P-gp inhibition, and P-gp induction by rifampicin. The disposition of rivaroxaban is more complex compared with apixaban because both hepatic and renal P-gp is considered to contribute to rivaroxaban elimination. Furthermore, organic anion transporter-3, a renal uptake transporter, may also contribute the elimination of rivaroxaban from systemic circulation. The models were verified with observed clinical drug-drug interactions with CYP3A and P-gp inhibitors. With the developed models, the predicted area under the concentration time curve and maximum concentration ratios were 0.43 and 0.48, respectively, for apixaban, and 0.50-0.52 and 0.72-0.73, respectively, for rivaroxaban when coadministered with 600 mg multiple doses of rifampicin and that were very close to observed data. The impact of each of the elimination pathways was assessed for rivaroxaban, and inhibition of CYP3A led to a larger impact over intestinal and hepatic P-gp. Inhibition of renal organic anion transporter-3 or P-gp led to an overall modest interaction. The developed apixaban and rivaroxaban models can be further applied to the investigation of interactions with other P-gp and/or CYP3A4 inhibitors and inducers.

    Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial Fibrillation; Biological Transport; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Embolism; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridones; Rifampin; Rivaroxaban; Stroke; Venous Thromboembolism

2020
What is this image? 2019: Image 1 result : Multimodal imaging in the diagnosis of infective endocarditis complicated with embolic acute myocardial infarction.
    Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2019, Volume: 26, Issue:4

    Topics: Aged, 80 and over; Diabetes Mellitus, Type 2; Doxycycline; Echocardiography; Electroencephalography; Embolism; Endocarditis; Fever; Fluorodeoxyglucose F18; Heart Valve Prosthesis; Humans; Hypertension; Magnetic Resonance Imaging; Male; Myocardial Infarction; Positron Emission Tomography Computed Tomography; Rifampin; Treatment Outcome

2019
Lemierre's syndrome: An unusual presentation.
    Medecine et maladies infectieuses, 2015, Volume: 45, Issue:8

    Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Cervical Vertebrae; Clindamycin; Drug Therapy, Combination; Embolism; Female; Gram-Positive Bacterial Infections; Headache; Humans; Lemierre Syndrome; Myalgia; Peptostreptococcus; Retropharyngeal Abscess; Rifampin; Spondylitis; Tomography, X-Ray Computed; Young Adult

2015
Endocarditis due to anaerobic gram-negative bacilli.
    The American journal of medicine, 1973, Volume: 54, Issue:4

    Topics: Bacteria; Bacteroides; Bacteroides Infections; Chloramphenicol; Embolism; Endocarditis, Bacterial; Erythromycin; Humans; Lincomycin; Male; Microbial Sensitivity Tests; Middle Aged; Penicillin Resistance; Rifampin; Tetracycline; Vancomycin

1973